Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Fast Track Articles
  5. Fast Track Article
image of Prediction of the Prognosis and Treatment Responses Based on the Characteristics of Disulfidptosis-Related Genes in Patients with Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma
file format pdf download PDF

Abstract

Background

Disulfidptosis is a new type of regulatory cell death (RCD), but the pathophysiological functions and mechanisms of DRGs in CESC remain to be examined.

Aims

This study explored the mutation status of disulfidptosis-related genes (DRGs) in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC).

Objective

After analyzing the mutation profiles of DRGs in CESC, this study established a prognostic model for CESC and also explored the differences in immune infiltration (accumulation of immune system cells in tissues or organs), related enriched pathways, and drug sensitivity between high-risk and low-risk CESC groups.

Methods

The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) were accessed to source related data. The mutation profiles of DRGs in CESC were analyzed using Mutect2 software, and disulfidptosis scores were calculated by ssGSEA. WGCNA was performed to identify modular genes, which were further filtered and used to formulate a risk model by applying the survival and glmnet packages. Low- and high-risk groups of CESC patients were classified using the survminer package. GSEA was performed to conduct pathway analysis, and immune infiltration was assessed using the MCPcounter package, ESTIMATE, and TIMER algorithms. Finally, immunotherapy response and drug sensitivity were analyzed using the TIDE method and the pRRophetic package, respectively.

Results

Except for , and were found to be the DRGs significantly mutated in CESC. The six genes were integrated to develop a RiskScore model with a relatively high Area Under the Curve (AUC) value. Significant differences between the two risk groups were determined, indicating that the model was highly reliable. Notably, the low-risk group was enriched in energy metabolism-correlated pathways, while the high-risk group was primarily enriched in immune-correlated pathways. The high-risk group showed higher immune cell activity, higher TIDE score, and more B cells than the low-risk group. Drug sensitivity study revealed that the high-risk group was more sensitive to chemotherapy drugs.

Conclusion

This study provides novel insights into CESC prognosis, immunotherapy, and drug development, contributing to the clinical treatment for CESC.

© 2025 The Author(s). Published by Bentham Science Publishers
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303374396250129111340
2025-02-12
2025-05-06

  • From This Site

    /content/journals/emiddt/10.2174/0118715303374396250129111340
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. Bray F. Laversanne M. Sung H. Ferlay J. Siegel R.L. Soerjomataram I. Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024 74 3 229 263 10.3322/caac.21834 38572751
    [Google Scholar]
  2. Small W. Jr Bacon M.A. Bajaj A. Chuang L.T. Fisher B.J. Harkenrider M.M. Jhingran A. Kitchener H.C. Mileshkin L.R. Viswanathan A.N. Gaffney D.K. Cervical cancer: A global health crisis. Cancer 2017 123 13 2404 2412 10.1002/cncr.30667 28464289
    [Google Scholar]
  3. Charakorn C. Thadanipon K. Chaijindaratana S. Rattanasiri S. Numthavaj P. Thakkinstian A. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis. Gynecol. Oncol. 2018 150 1 190 200 10.1016/j.ygyno.2018.03.056 29606483
    [Google Scholar]
  4. Johnson C.A. James D. Marzan A. Armaos M. Cervical cancer: An overview of pathophysiology and management. Semin. Oncol. Nurs. 2019 35 2 166 174 10.1016/j.soncn.2019.02.003 30878194
    [Google Scholar]
  5. Gao W. Ma Q. Tang C. Zhan Y. Duan Y. Ni H. Xu Y. Microenvironment and related genes predict outcomes of patients with cervical cancer: Evidence from TCGA and bioinformatic analysis. Biocell 2020 44 4 597 605 10.32604/biocell.2020.011328
    [Google Scholar]
  6. Vu M. Yu J. Awolude O.A. Chuang L. Cervical cancer worldwide. Curr. Probl. Cancer 2018 42 5 457 465 10.1016/j.currproblcancer.2018.06.003 30064936
    [Google Scholar]
  7. Cohen P.A. Jhingran A. Oaknin A. Denny L. Cervical cancer. Lancet 2019 393 10167 169 182 10.1016/S0140‑6736(18)32470‑X 30638582
    [Google Scholar]
  8. Paik E.S. Lim M.C. Kim M.H. Kim Y.H. Song E.S. Seong S.J. Suh D.H. Lee J.M. Lee C. Choi C.H. Prognostic model for survival and recurrence in patients with early-stage cervical cancer: A Korean gynecologic oncology group study (KGOG 1028). Cancer Res. Treat. 2020 52 1 320 333 10.4143/crt.2019.124 31401822
    [Google Scholar]
  9. Shahrajabian M.H. Sun W. Survey on Multi-omics, and Multi-omics data analysis, integration and application. Curr. Pharm. Anal. 2023 19 4 267 281 10.2174/1573412919666230406100948
    [Google Scholar]
  10. Yi Y. Zheng J. Zhou Y. Liu Z. Weng D. Role of pyroptotic cell death in the pathogenesis of NASH. Biocell 2020 44 1 7 11 10.32604/biocell.2020.08686
    [Google Scholar]
  11. Karati D. Kumar D. Molecular insight into the apoptotic mechanism of cancer cells: An explicative review. Curr. Mol. Pharmacol. 2024 17 e18761429273223 10.2174/0118761429273223231124072223 38389419
    [Google Scholar]
  12. Liu X. Zhuang L. Gan B. Disulfidptosis: Disulfide stress–induced cell death. Trends Cell Biol. 2024 34 4 327 337 10.1016/j.tcb.2023.07.009 37574347
    [Google Scholar]
  13. Liu X. Nie L. Zhang Y. Yan Y. Wang C. Colic M. Olszewski K. Horbath A. Chen X. Lei G. Mao C. Wu S. Zhuang L. Poyurovsky M.V. James You M. Hart T. Billadeau D.D. Chen J. Gan B. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat. Cell Biol. 2023 25 3 404 414 10.1038/s41556‑023‑01091‑2 36747082
    [Google Scholar]
  14. Hong S. Zhang Y. Wang D. Wang H. Zhang H. Jiang J. Chen L. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma. Aging 2024 16 11 9972 9989 10.18632/aging.205911 38862217
    [Google Scholar]
  15. Zheng P. Zhou C. Ding Y. Duan S. Disulfidptosis: A new target for metabolic cancer therapy. J. Exp. Clin. Cancer Res. 2023 42 1 103 10.1186/s13046‑023‑02675‑4 37101248
    [Google Scholar]
  16. Meng Y. Chen X. Deng G. Disulfidptosis: A new form of regulated cell death for cancer treatment. Mol. Biomed. 2023 4 1 18 10.1186/s43556‑023‑00132‑4 37318660
    [Google Scholar]
  17. He J. Wang X. Chen K. Zhang M. Wang J. The amino acid transporter SLC7A11-mediated crosstalk implicated in cancer therapy and the tumor microenvironment. Biochem. Pharmacol. 2022 205 115241 10.1016/j.bcp.2022.115241 36084707
    [Google Scholar]
  18. Gu Y. Albuquerque C.P. Braas D. Zhang W. Villa G.R. Bi J. Ikegami S. Masui K. Gini B. Yang H. Gahman T.C. Shiau A.K. Cloughesy T.F. Christofk H.R. Zhou H. Guan K.L. Mischel P.S. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT. Mol. Cell 2017 67 1 128 138.e7 10.1016/j.molcel.2017.05.030 28648777
    [Google Scholar]
  19. Wang Y. Deng Y. Xie H. Cao S. Hub gene of disulfidptosis-related immune checkpoints in breast cancer. Med. Oncol. 2023 40 8 222 10.1007/s12032‑023‑02073‑y 37402987
    [Google Scholar]
  20. Qi C. Ma J. Sun J. Wu X. Ding J. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma. Aging 2023 15 11 5075 5095 10.18632/aging.204782 37315289
    [Google Scholar]
  21. Feng Z. Zhao Q. Ding Y. Xu Y. Sun X. Chen Q. Zhang Y. Miao J. Zhu J. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies. J. Cancer Res. Clin. Oncol. 2023 149 13 11157 11170 10.1007/s00432‑023‑05006‑4 37347261
    [Google Scholar]
  22. Yang L. Liu J. Li S. Liu X. Zheng F. Xu S. Fu B. Xiong J. Based on disulfidptosis, revealing the prognostic and immunological characteristics of renal cell carcinoma with tumor thrombus of vena cava and identifying potential therapeutic target AJAP1. J. Cancer Res. Clin. Oncol. 2023 149 12 9787 9804 10.1007/s00432‑023‑04877‑x 37247081
    [Google Scholar]
  23. Liu H. He S. Tan L. Li M. Chen C. Tan R. Disulfidptosis-related long non-coding RNAs predict prognosis and indicate therapeutic response in non-small cell lung carcinoma. Oncologie 2024 26 1 151 165 10.1515/oncologie‑2023‑0384
    [Google Scholar]
  24. Zhou S. Liu J. Wan A. Zhang Y. Qi X. Epigenetic regulation of diverse cell death modalities in cancer: A focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis. J. Hematol. Oncol. 2024 17 1 22 10.1186/s13045‑024‑01545‑6 38654314
    [Google Scholar]
  25. Van der Auwera G.A. Carneiro M.O. Hartl C. Poplin R. del Angel G. Levy-Moonshine A. Jordan T. Shakir K. Roazen D. Thibault J. Banks E. Garimella K.V. Altshuler D. Gabriel S. DePristo M.A. From FastQ data to high confidence variant calls: The genome analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013 43 1110 11.10.1 11.10.33
    [Google Scholar]
  26. Song Z. Yu J. Wang M. Shen W. Wang C. Lu T. Shan G. Dong G. Wang Y. Zhao J. CHDTEPDB: Transcriptome expression profile database and interactive analysis platform for congenital heart disease. Congenit. Heart Dis. 2023 18 6 693 701 10.32604/chd.2024.048081
    [Google Scholar]
  27. Therneau T.J.R.p.v. A package for survival analysis in S. R package version 2015 2 7 2014
    [Google Scholar]
  28. Friedman J. Hastie T. Tibshirani R. Narasimhan B. Tay K. Simon N. Qian J. Package ‘glmnet’. CRAN R Repositary 2021 595
    [Google Scholar]
  29. Kolde R. Package ‘pheatmap’ R package version 2015 1 7 790
    [Google Scholar]
  30. Yu G. Wang L.G. Han Y. He Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012 16 5 284 287 10.1089/omi.2011.0118 22455463
    [Google Scholar]
  31. Becht E. Giraldo N.A. Lacroix L. Buttard B. Elarouci N. Petitprez F. Selves J. Laurent-Puig P. Sautès-Fridman C. Fridman W.H. de Reyniès A. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016 17 1 218 10.1186/s13059‑016‑1070‑5 27765066
    [Google Scholar]
  32. Yoshihara K. Shahmoradgoli M. Martínez E. Vegesna R. Kim H. Torres-Garcia W. Treviño V. Shen H. Laird P.W. Levine D.A. Carter S.L. Getz G. Stemke-Hale K. Mills G.B. Verhaak R.G.W. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013 4 1 2612 10.1038/ncomms3612 24113773
    [Google Scholar]
  33. Geeleher P. Cox N. Huang R.S. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One 2014 9 9 e107468 10.1371/journal.pone.0107468 25229481
    [Google Scholar]
  34. Shen W. Song Z. Zhong X. Huang M. Shen D. Gao P. Qian X. Wang M. He X. Wang T. Li S. Song X. Sangerbox: A comprehensive, interaction‐friendly clinical bioinformatics analysis platform. iMeta 2022 1 3 e36 10.1002/imt2.36 38868713
    [Google Scholar]
  35. Siegel R.L. Miller K.D. Fuchs H.E. Jemal A. Cancer statistics, 2021. CA Cancer J. Clin. 2021 71 1 7 33 10.3322/caac.21654 33433946
    [Google Scholar]
  36. Momenimovahed Z. Mazidimoradi A. Amiri S. Nooraie Z. Allahgholi L. Salehiniya H. Temporal trends of cervical cancer between 1990 and 2019, in Asian countries by geographical region and socio-demographic index, and comparison with global data. Oncologie 2023 25 2 119 148 10.1515/oncologie‑2022‑1009
    [Google Scholar]
  37. Arbyn M. Weiderpass E. Bruni L. de Sanjosé S. Saraiya M. Ferlay J. Bray F. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health 2020 8 2 e191 e203 10.1016/S2214‑109X(19)30482‑6 31812369
    [Google Scholar]
  38. Machesky L.M. Deadly actin collapse by disulfidptosis. Nat. Cell Biol. 2023 25 3 375 376 10.1038/s41556‑023‑01100‑4 36918690
    [Google Scholar]
  39. Xie J. Deng X. Xie Y. Zhu H. Liu P. Deng W. Ning L. Tang Y. Sun Y. Tang H. Cai M. Xie X. Zou Y. Multi‐omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple‐negative breast cancer. MedComm 2024 5 3 e502 10.1002/mco2.502 38420162
    [Google Scholar]
  40. Wu Y. Yang M. Fan J. Peng Y. Deng L. Ding Y. Yang R. Zhou J. Miao D. Fu Q. Deficiency of osteoblastic Arl6ip5 impaired osteoblast differentiation and enhanced osteoclastogenesis via disturbance of ER calcium homeostasis and induction of ER stress-mediated apoptosis. Cell Death Dis. 2014 5 10 e1464 e1464 10.1038/cddis.2014.427 25321471
    [Google Scholar]
  41. Cho O. Kim D.W. Cheong J.Y. Screening plasma exosomal RNAs as diagnostic markers for cervical cancer: An analysis of patients who underwent primary chemoradiotherapy. Biomolecules 2021 11 11 1691 10.3390/biom11111691 34827689
    [Google Scholar]
  42. Turnbull J. Tiberia E. Pereira S. Zhao X. Pencea N. Wheeler A.L. Yu W.Q. Ivovic A. Naranian T. Israelian N. Draginov A. Piliguian M. Frankland P.W. Wang P. Ackerley C.A. Giacca A. Minassian B.A. Deficiency of a glycogen synthase-associated protein, Epm2aip1, causes decreased glycogen synthesis and hepatic insulin resistance. J. Biol. Chem. 2013 288 48 34627 34637 10.1074/jbc.M113.483198 24142699
    [Google Scholar]
  43. Challa B. Frankel W.L. Knight D. Pearlman R. Hampel H. Chen W. EPM2AIP1 immunohistochemistry is inadequate as a surrogate marker for MLH1 promoter hypermethylation testing in colorectal cancer. Hum. Pathol. 2024 150 74 77 10.1016/j.humpath.2024.06.017 38945374
    [Google Scholar]
  44. Froese D.S. Michaeli A. McCorvie T.J. Krojer T. Sasi M. Melaev E. Goldblum A. Zatsepin M. Lossos A. Álvarez R. Escribá P.V. Minassian B.A. von Delft F. Kakhlon O. Yue W.W. Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. Hum. Mol. Genet. 2015 24 20 5667 5676 10.1093/hmg/ddv280 26199317
    [Google Scholar]
  45. Ding Z. Yang H.W. Xia T.S. Wang B. Ding Q. Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction. Int. J. Mol. Med. 2015 36 2 473 484 10.3892/ijmm.2015.2237 26046131
    [Google Scholar]
  46. Zhang J. Jun Cho S. Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc. Natl. Acad. Sci. USA 2010 107 21 9614 9619 10.1073/pnas.0912594107 20457941
    [Google Scholar]
  47. Jiang Y. Xu E. Zhang J. Chen M. Flores E. Chen X. The Rbm38-p63 feedback loop is critical for tumor suppression and longevity. Oncogene 2018 37 21 2863 2872 10.1038/s41388‑018‑0176‑5 29520104
    [Google Scholar]
  48. Ye J. Liang R. Bai T. Lin Y. Mai R. Wei M. Ye X. Li L. Wu F. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2018 37 1 212 10.1186/s13046‑018‑0852‑x 30176896
    [Google Scholar]
  49. Yang L. Zhang Y. Ling C. Heng W. RNPC1 inhibits non-small cell lung cancer progression via regulating miR-181a/CASC2 axis. Biotechnol. Lett. 2018 40 3 543 550 10.1007/s10529‑017‑2504‑1 29288351
    [Google Scholar]
  50. Cheng G. Ji C. Yang N. Meng L. Ding Y. Wei J. RNA-binding protein RBM38: Acting as a tumor suppressor in colorectal cancer. Int. J. Clin. Exp. Med. 2016 9 4 7115 7126
    [Google Scholar]
  51. Zou C. Wan Y. He L. Zheng J.H. Mei Y. Shi J. Zhang M. Dong Z. Zhang D. RBM38 in cancer: Role and mechanism. Cell. Mol. Life Sci. 2021 78 1 117 128 10.1007/s00018‑020‑03593‑w 32642788
    [Google Scholar]
  52. Zhou M. Han Y. Jiang J. Ulk4 promotes Shh signaling by regulating Stk36 ciliary localization and Gli2 phosphorylation. eLife 2023 12 RP88637 10.7554/eLife.88637.3 38096226
    [Google Scholar]
  53. Lang B. Pu J. Hunter I. Liu M. Martin-Granados C. Reilly T.J. Gao G-D. Guan Z-L. Li W-D. Shi Y-Y. He G. He L. Stefánsson H. St Clair D. Blackwood D.H. McCaig C.D. Shen S. Recurrent deletions of ULK4 in schizophrenia: A gene crucial for neuritogenesis and neuronal motility. J. Cell Sci. 2014 127 Pt 3 630 640 24284070
    [Google Scholar]
  54. Lee S.U. Maeda T. POK/ZBTB proteins: An emerging family of proteins that regulate lymphoid development and function. Immunol. Rev. 2012 247 1 107 119 10.1111/j.1600‑065X.2012.01116.x 22500835
    [Google Scholar]
  55. Lim J.H. Zinc finger and BTB domain-containing protein 3 is essential for the growth of cancer cells. BMB Rep. 2014 47 7 405 410 10.5483/BMBRep.2014.47.7.075 24856827
    [Google Scholar]
  56. Yamaguchi R. Perkins G. Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. Cancer Biol. Ther. 2018 19 9 745 754 10.1080/15384047.2018.1470722 29723108
    [Google Scholar]
  57. Najafi M. Farhood B. Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J. Cell. Biochem. 2019 120 3 2782 2790 10.1002/jcb.27681 30321449
    [Google Scholar]
  58. Mohan V. Das A. Sagi I. Emerging roles of ECM remodeling processes in cancer. Semin. Cancer Biol. 2020 62 192 200 10.1016/j.semcancer.2019.09.004 31518697
    [Google Scholar]
  59. Biteau B. Hochmuth C.E. Jasper H. Maintaining tissue homeostasis: Dynamic control of somatic stem cell activity. Cell Stem Cell 2011 9 5 402 411 10.1016/j.stem.2011.10.004 22056138
    [Google Scholar]
  60. Sutherland T.E. Dyer D.P. Allen J.E. The extracellular matrix and the immune system: A mutually dependent relationship. Science 2023 379 6633 eabp8964 10.1126/science.abp8964 36795835
    [Google Scholar]
  61. Li X. Bechara R. Zhao J. McGeachy M.J. Gaffen S.L. IL-17 receptor–based signaling and implications for disease. Nat. Immunol. 2019 20 12 1594 1602 10.1038/s41590‑019‑0514‑y 31745337
    [Google Scholar]
  62. Zhao J. Chen X. Herjan T. Li X. The role of interleukin-17 in tumor development and progression. J. Exp. Med. 2020 217 1 e20190297 10.1084/jem.20190297 31727782
    [Google Scholar]
  63. Sarvaria A. Madrigal J.A. Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell. Mol. Immunol. 2017 14 8 662 674 10.1038/cmi.2017.35 28626234
    [Google Scholar]
  64. Tokunaga R. Naseem M. Lo J.H. Battaglin F. Soni S. Puccini A. Berger M.D. Zhang W. Baba H. Lenz H.J. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat. Rev. 2019 73 10 19 10.1016/j.ctrv.2018.12.001 30551036
    [Google Scholar]
  65. Yamada Y. Namba K. Fujii T. Cardiac muscle thin filament structures reveal calcium regulatory mechanism. Nat. Commun. 2020 11 1 153 10.1038/s41467‑019‑14008‑1 31919429
    [Google Scholar]
  66. Esteves F. Rueff J. Kranendonk M. The central role of cytochrome P450 in xenobiotic metabolism—A brief review on a fascinating enzyme family. J. Xenobiot. 2021 11 3 94 114 10.3390/jox11030007 34206277
    [Google Scholar]
  67. Nolfi-Donegan D. Braganza A. Shiva S. Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 2020 37 101674 10.1016/j.redox.2020.101674 32811789
    [Google Scholar]
  68. Klinge S. Woolford J.L. Jr Ribosome assembly coming into focus. Nat. Rev. Mol. Cell Biol. 2019 20 2 116 131 10.1038/s41580‑018‑0078‑y 30467428
    [Google Scholar]
  69. Tabuchi C. Sul H.S. Signaling pathways regulating thermogenesis. Front. Endocrinol. 2021 12
    [Google Scholar]
  70. Webster R.M. The immune checkpoint inhibitors: Where are we now? Nat. Rev. Drug Discov. 2014 13 12 883 884 10.1038/nrd4476 25345674
    [Google Scholar]
  71. Tekguc M. Wing J.B. Osaki M. Long J. Sakaguchi S. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 2021 118 30 e2023739118 10.1073/pnas.2023739118 34301886
    [Google Scholar]
  72. Zhou X. Wang Y. Zheng J. Wang S. Liu C. Yao X. Ren Y. Wang X. Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer. Front. Genet. 2022 13 990301 10.3389/fgene.2022.990301 36276934
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303374396250129111340
Loading
Prediction of the Prognosis and Treatment Responses Based on the Characteristics of Disulfidptosis-Related Genes in Patients with Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma
Bentham Science Publishers ; https://doi.org/10.2174/0118715303374396250129111340
/content/journals/emiddt/10.2174/0118715303374396250129111340
/content/journals/emiddt/10.2174/0118715303374396250129111340
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: risk model ; immune infiltration ; drug sensitivity ; Disulfidptosis-related gene ; tumor microenvironment ; cervical squamous cell carcinoma and endocervical adenocarcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test